Local gene therapy with CTLA4-immunoglobulin fusion protein in experimental allergic encephalomyelitis

European Journal of Immunology

Volumn 28, Issue 12, 1998, Pages 3904-3916

  Croxford, J Ludovic ^a   O'Neill, Janet K ^a   Ali, Robin R ^a   Browne, Kylie ^b   Byrnes, Andrew P ^c,d   Dallman, Maggie J ^e   Wood, Matthew J A ^c   Feldmann, Marc ^b   Baker, David ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Co stimulation; CTLA4 Ig; Experimental allergic encephalomyelitis; Gene therapy

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HYBRID PROTEIN; IMMUNOGLOBULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY;

ADENOVIRUS; ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GENE THERAPY; IMMUNOTHERAPY; INTRACEREBRAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0031739190     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(199812)28:12<3904::AID-IMMU3904>3.0.CO;2-5     Document Type: Article

References (50)

1. Boise, L. H., Noel, A. J. and Thompson, C. B., CD28 and apoptosis. Curr. Opin. Immunol. 1995. 7: 620-625.
2. Karandikar, N. J.,. Vanderlugt, C. L., Walunas, T. L., Miller, S. D. and Bluestone, J. A., CTLA-4: a negative regulator of autoimmune disease. J. Exp. Med. 1996. 184: 783-788.
3. Perrin, P. J., Maldonado, J. H., Davis, T. A., June, C. H. and Racke, M. K., CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis. J. Immunol. 1996. 157: 1333-1336.
4. Finck, B. K., Linsley, P. S. and Wofsy, D., Treatment of murine lupus with CTLA4lg. Science 1994. 265: 1225-1227.
5. Wallace, P. M., Rodgers, J. N., Leytze, G. M., Johnson, J. S. and Linsley, P. S., Induction and reversal of long-lived specific unresponsivenes to a T-dependent antigen following CTLA4lg treatment. J. Immunol. 1995. 154: 5885-5895.
6. Steurer, W., Nickerson, P. W., Steele, A. W., Steiger, J., Zheng, X. X. and Strom, T. E. E., Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance. J. Immunol. 1995. 155: 1165-1174.
7. Tang, A., Judge, T. A., Nickoloff, B. J. and Turka, L. A., Suppression of murine allergic contact dermatitis by CTLA4lg. Tolerance induction of Th2 responses requires additional blockade of CD40-ligand. J. Immunol. 1996. 157: 117-125.
8. Steinman, L. S., Rosenbaum, J. T., Sriram, S. and McDevitt, H. O., In vivo effects of antibodies to immune response gene products: prevention of experimental allergic. Proc. Natl. Acad. Sci. USA 1981. 78: 7111-7114.
9. Smith, R. M., Morgan, A. and Wraith, D. C., Anti-class II MHC antibodies prevent and treat EAE without APC depletion. Immunology 1994. 83: 1-8.
10. Perrin, P. J., Scott, D., Quigley, L., Albert, P. S., Feder, O., Gray, G. S., Abe, R., June, C. H. and Racke, M. R., Role of B7 : CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. J. Immunol. 1995. 154: 1481-1490.
11. Cross, A. H., Girard, T. J., Giacoletto, K. S., Evans, R. J., Keeling, R. M., Lin, R. F., Trotter, J. L. and Karr, R. W., Long term inhibition of murine experimental autoimmune encephalomyelitis using CTLA4-Fc supports a key role for CD28 costimulation. J. Clin. Invest. 1995. 95: 2783-2789.
12. Arima, T., Rehman, A., Hickey, W. F. and Flye, M. W., Inhibition by CTLA4lg of experimental allergic encephalomyelitis. J. Immunol. 1996. 156: 4916-4924.
13. Khoury, S. J., Akalin, E., Chandraker, A., Turka, L. A., Linsley, P. S., Sayegh, M. H. and Hancock, W. W., CD28-B7 co-stimulatory blockade by CTLA4lg prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J. Immunol. 1995. 155: 4521-4524.
14. Perrin, P. J., Scott, D., Davis, T. A., Gray, G. S., Doggett, M. J., Abe, R., June, C. H. and Racke, M. K., Opposing effects of CTLA4-lg and anti-CD80 (B7-1) plus anti-CD86 (B7-2) on experimental allergic encephalomyelitis. J. Neuroimmunol. 1996. 65: 31-39.
15. Croft, M., Bradley, L. M. and Swain, S. L., Naïve versus memory CD4 T cell response to antigen: Memory cells are less dependent on accessory cell costimulation and can respond to many antigen-pesenting cell types including resting B cells. J. Immunol. 1994. 152: 2675-2685.
16. Wekerle, H., Linington, C., Lassman, H. and Meyerman, R., Cellular immune reactivity within the CNS. Trends Neurosci. 1986. 9: 271-277.
17. Hickey, W. F., Hsu, B. L. and Kimura, H., T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 1991. 28: 254-260.
18. Butter, C., O'Neill, J. K., Baker, D., Gschmeissner, S. E. and Turk, J. L., An immunoelectronmicroscopical study of the expression of class II MHC during chronic relapsing experimental allergic encephalomyelitis. J. Neuroimmunol. 1991. 20: 45-51.
19. Butter, C., Baker, D., O'Neill, J. K. and Turk, J. L., Mononuclear cell traffic and plasma protein extravasation into the CNS during chronic relapsing experimental allergic encephalomyelitis in Biozzi AB/H mice. J. Neurol. Sci. 1991. 104: 9-12.
20. O'Neill, J. K., Baker, D., Butter, C., Allen, S. J., Waldmann, H. and Turk, J. L., Control of immune mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J. Neuroimmunol. 1993. 45: 1-14.
21. O'Neill, J. K., Baker, D., Davison, A. N., Jaffee, B. D., Maggon, K. K. and Turk, J. L., Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood brain barrier:elucidation by the action of Brequinar sodium. J. Neuroimmunol. 1991. 38: 53-62.
22. Baker, D., O'Neill, J. K., Davison, A. N. and Turk, J. L., Control of immune-mediated disease of the central nervous system requires the use of a neuroactive agent: elucidation by the action of mitoxantrone. Clin. Exp. Immunol. 1992. 90: 124-128.
23. Baker, D., Butler, D., Scallon, B. J., O'Neill, J. K., Turk, J. L. and Feldmann, M., Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 1994. 24: 2040-2048.
24. Lenschow, D. J., Ho, S. C., Sattar, H., Rhee, L., Gray, G., Nabavi, N., Herold, K. C. and Bluestone, J. A., Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 1995. 181: 1145-1155,
25. Sayegh, M. H., Akalin, E., Hancock, W. W., Russell, M. E., Carpenter, C. B., Linsley, P. S. and Turka, L. A., CD28-B7 blockade after alloantigenic challenge in vivo inhibits Th1 cytokines but spares Th2. J. Exp. Med. 1995. 181: 1869-1874.
26. Webb, L. M. C., Walmsley, M. J. and Feldmann, M., Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: Requirement for both B7-1 and B7-2. Eur. J. Immunol 1996. 26: 2320-2328.
27. Williams, R. O., Ghrayeb, J., Feldmann, M. and Maini, R. N., Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 1995. 84: 433-439.
28. Srinivas, N. R., Weiner, R. S., Shyu, W. C., Calore, J. D., Tritschler, D., Tay, L. K., Lee, J. S., Greene, D. S. and Barbhaiya, R. H. A., Pharmacokinetic study of intravenous CTLA4lg, a novel immunosuppressive agent, in mice. J. Pharm. Sci. 1996. 85: 296-298.
29. Wallace, P. M., Johnson, J. S., MacMaster, J. F., Kennedy, K. A., Gladstone, P. and Linsley, P. S., CTLA4lg treatment ameliorates the lethality of murine graftversus-host disease across major histocompatibility complex barriers. Transplantation 1994. 58: 602-610.
30. Lane, P., Gerhard, W., Hubele, S., Lanzavecchia, A. and McConnell, F., Expression and functional properties of mouse B7/BB1 using a fusion protein between mouse CTLA4 and human γ1. Immunology 1993. 80: 56-61.
31. Vanderlugt, C. L., Karandikar, N. J., Lenschow, D. J., Dal Canto, M. C., Bluestone, J. A. and Miller, S. D., Treatment with intact anti-B7-1 mAb during disease remission enhances epitope spreading and exacerbates relapses in R-EAE. J. Neuroimmunol. 1997. 79: 113-118.
32. 14C-labelled cells during acute, chronic and relapsing experimental allergic encephalomyelitis. Lab. Invest. 1990. 62: 162-170.
33. Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe, M. N., Cuzner, M. L. and Hafler, D. A., Expression of co-stimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions. J. Exp. Med. 1995. 182: 1985-1996.
34. Kuchroo, V. K., Das, M. P., Brown, J. A., Ranger, A. M., Zamvil, S. S., Sobel, R. A., Weiner, H. L., Nabavi, N. and Glimcher, L. H., B7-1 and B7-2 co-stimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995. 80: 707-718.
35. Miller, S. D., Vanderlugt, C. L., Lenschow, D. J., Pope, J. G., Karandikar, N. J., Dal Canto, M. C. and Bluestone, J. A., Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical of murine EAE. Immunity 1995. 3: 739-745.
36. Reiser, H. and Schneeberger, E. E., Expression and function of B7-1 and B7-2 in hapten-induced contact sensitivity. Eur. J. Immunol. 1996. 26: 880-885.
37. Pearson, T. C., Alexander, D. Z., Corbascio, M., Hendrix, R., Ritchie, S. C., Linsley, P. S., Faherty, D. and Larsen, C. P., Analysis of the B7 co-stimulatory pathway in allograft rejection. Transplantation 1997. 63: 1463-1469.
38. Racke, M. K., Scott, D. E., Quigley, L., Gray, G. S., Abe, R., June, C. H. and Perrin, P. J., Distinct roles for B7-1 (CD80) and B7-2 (CD86) in the initiation of experimental allergic encephalomyelitis. J. Clin. Invest. 1995. 96: 2195-2203.
39. Croxford, J. L., Triantaphyllopoulous, K., Podajcer, O. L., Feldmann, M., Baker, D. and Chernajovsky, Y., Cytokine gene therapy in experimental allergic encephalomyelitis by injection of plasmid DNA-cationic liposome complex into the central nervous system. J. Immunol. 1998. 160: 5181-5187.
40. Wood, M. J., Charlton, H. M., Wood, K. J., Kajiwara, K. and Byrnes, A. P., Immune responses to adenovirus vectors in the nervous system. Trends Neurosci. 1996. 19: 497-501.
41. Byrnes, A. P., Rusby, J. E., Wood, M. J. and Charlton, H. M., Adenovirus gene transfer causes inflammation in the brain. Neuroscience 1995. 66: 1015-1024.
42. Kay, M. A., Holterman, A. X., Meuse, L., Gown, A., Ochs, H. D., Linsley, P. S. and Wilson, C. B., Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4lg administration. Nat. Genet. 1995. 11: 191-197.
43. Scholz, C., Patton, K. T., Anderson, D. E., Freeman, G. J. and Hafler, D. A., Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 co-stimulation. J. Immunol. 1998. 160: 1532-1538.
44. Lovett-Racke, A. E., Trotter, J. L., Lauber, J., Perrin, P. J., June, C. H. and Racke, M. K., Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated co-stimulation in multiple sclerosis patients. A marker of activated/memory cells. J. Clin. Invest. 1998. 101: 725-730.
45. Oi, V. T., Jones, P. P., Coding, J. W., Herzenberg, L. A. and Herzenberg, L. A., Properties of monoclonal antibodies to mouse Ig allotypes, H-2 and la antigens. Curr. Top. Microbiol. Immunol. 1978. 81: 115-129.
46. Nabavi, N., Freeman, G. J., Gault, A., Godfrey, D., Nadler, L. M. and Glimcher, L. H., Signalling through the MHC class II cytoplasmic domain is required for antigen presentation and induces B7 expression. Nature 1992. 360: 266-268.
47. Chen, C., Faherty, D. A., Gault, A., Connaughton, S. E., Powers, G. D., Godfrey, D. I. and Nabavi, N., Monoclonal antibody 2D10 recognizes a novel Tcell costimulatory molecule on activated murine B lymphocytes. J. Immunol. 1994. 152: 2105-2114.
48. Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B. and Bluestone, J. A., CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994. 1: 405-413.
49. Oral, H. B., Larkin, D. F., Fehervari, Z., Byrnes, A. P., Rankin, A. M., Haskard, D. O., Wood, M. J., Dallman, M. J. and George, A. J., Ex vivo adenovirus-mediated gene transfer and immunomodulatory protein production in human cornea. Gene Ther. 1997. 4: 639-647.
50. Kolls, J. K., Lei, D., Nelson, S., Summer, W. R., Greenberg, S. and Beutler, B., Adenovirus-mediated blockade of tumor necrosis factor in mice protects against endotoxic shock yet impairs pulmonary host defence. J Infect. Dis. 1995. 171: 570-575.